Last reviewed · How we verify
NCT04347460: COVIDHLH
Establishing a COVID-19 Prospective Cohort for Identification of Secondary HLH
trial in COVID in 20 participants. Status unknown.
1 July 2020
Quick facts
| Lead sponsor | Technical University of Munich |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 27 March 2020 |
| Primary completion | 1 July 2020 |
| Estimated completion | 31 August 2020 |
| Sites | 1 location across Germany |
Conditions studied
- COVID — all drugs for COVID →
Sponsor
Technical University of Munich
Who can join
18 and older, any sex, with COVID. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
SARS-CoV2 has become a pandemic disease putting an enormous burden on health care systems around the world. A considerable amount of patients require intensive care treatment for Covid-19 associated pneumonia. At this point there is no specific treatment, apart from supportive intensive care treatment protocols for severe COVID-19 disease.The latest reports describe massive hyperinflammation in some of the severe COVID-19 patients, which is not a typical finding in virus associated pneumonia. The H-score and the modified HLH 2004 score offer diagnostic tools, that help establishing the diagnosis of HLH. Even more important is the expert clinical judgment to establish the diagnosis of sHLH.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Title: Cytokine release syndrome is not usually caused by secondary hemophagocytic lymphohistiocytosis in a cohort of 19 critically ill COVID-19 patients.
Lorenz G, Moog P, Bachmann Q, La Rosée P, et al · · 2020 · cited 25× · PMID 33106497 · DOI 10.1038/s41598-020-75260-w -
Hemophagocytic lymphohistiocytosis in COVID-19: Case reports of a stepwise approach.
Schnaubelt S, Tihanyi D, Strassl R, Schmidt R, et al · · 2021 · cited 17× · PMID 33761694 · DOI 10.1097/md.0000000000025170 -
COVID-19 Associated Hemophagocytic Lymphohistiocytosis and Coagulopathy: Targeting the Duumvirate.
Bhattacharjee S, Banerjee M, Pal R. · · 2020 · cited 15× · PMID 32583809 -
Cytokine release syndrome is not usually caused by secondary hemophagocytic lymphohistiocytosis in a cohort of 19 critically ill COVID-19 patients
Lorenz G, Moog P, Bachmann Q, Rosee PL, et al · · 2020 · DOI 10.21203/rs.3.rs-31847/v1
Verify or expand the search:
- PubMed search for NCT04347460
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID
Currently open trials in the same condition.
- NCT06744660 — Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test · NA · recruiting
- NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
- NCT04447833 — Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome · Phase 1 · active not recruiting
- NCT04351347 — The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment · Phase 2, PHASE3 · recruiting
- NCT04382846 — Novel Regimens in COVID-19 Treatment · Phase 3 · recruiting
Other Technical University of Munich trials
Trials by the same sponsor.
- NCT07519811 — LLM-Generated Plain-Language Patient Synopses to Improve Comprehension in Hematology and Oncology (oncOPAL) · NA · recruiting
- NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting
- NCT07077005 — Mavacamten Enables Exercise in Hypertrophic Obstructive Cardiomyopathy · NA · recruiting
- NCT07212699 — Development of an Outcome Score for Patients With Knee Osteoarthritis and Knee Joint Endoprosthesis Using an App · NA · recruiting
- NCT06823271 — Haemodynamics and Ventricular Arrhythmias During Exercise in Patients With Arrhythmogenic Cardiomyopathy · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04347460 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Technical University of Munich
- Last refreshed: 15 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04347460.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing